Home > Dermatology > PFGC 2021 > Genes in Psoriasis and Psoriatic Arthritis > HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By
Dr Oras Alabas, University of Manchester, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
PFGC 2021
A real-world analysis of the BADBIR registry showed that human leukocyte antigen (HLA)-C*06:02 status is a predictive biomarker of drug survival for ustekinumab and perhaps adalimumab but not for etanercept or secukinumab. In contrast, no association was found between drug survival and HLA-C*06:02 status of patients who discontinued treatment due to adverse events. Thus, the present study, presented by Dr Oras Alabas (University of Manchester, UK), aimed to investigate whether HLA-C*06:02 affects the discontinuation of biologics in a large cohort of psoriasis patients in the real world [3]. BADBIR is a UK pharmacovigilance register designed to assess the long-term safety of newer drugs by following a real-world population of psoriasis patients of different sex, age, ethnicity, body mass index (BMI), and comorbidities. The population consisted of patients with chronic plaque psoriasis registered to BADBIR from 2007–2020. All patients were treated with adali...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on